Loading...
•
Dec 31, 2022
Xencor Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
Xencor reported a net loss of $12.0 million for the fourth quarter of 2022, compared to a net income of $73.1 million for the same period in 2021. Total revenue for the fourth quarter was $21.6 million, compared to $154.0 million for the same period in 2021. The company's cash, cash equivalents, receivables, and marketable debt securities totaled $613.5 million as of December 31, 2022.
Advanced internal portfolio of XmAb drug candidates.
Initiated Phase 1 studies for two novel T-cell engagers, XmAb819 and XmAb808.
Expect to further expand wholly owned portfolio by initiating a Phase 1 study for XmAb662.
Anticipate submitting an IND for XmAb541.
Forward Guidance
Xencor expects to end 2023 with between $425 million and $475 million in cash, cash equivalents, receivables and marketable debt securities, and to have cash to fund research and development programs and operations through the end of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...